|
US2020078364A1
|
|
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|
|
AU2018359248A1
|
|
Compounds and compositions for treating hematological disorders
|
|
CN109923117A
|
|
Use the combination therapy of the phosphoinositide 3-kinase inhibitor with zinc bound fraction
|
|
WO2019061324A1
|
|
Crystal forms of immunomodulators
|
|
AU2017213826A1
|
|
Mutant smoothened and methods of using the same
|
|
AU2016203958A1
|
|
Pyridyl Inhibitors of Hedgehog Signalling
|
|
AU2015252098A1
|
|
Mutant smoothened and methods of using the same
|
|
AU2015203844A1
|
|
Inhibitors of IAP
|
|
AU2015200733A1
|
|
Quinazoline based egfr inhibitors containing a zinc binding moiety
|
|
AU2015214264A1
|
|
Mutant Smoothened and methods of using the same
|
|
AU2014280913A1
|
|
Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|
|
US2014018368A1
|
|
Hedgehog antagonists having zinc binding moieties
|
|
AU2013206342A1
|
|
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
|
|
AU2013204088A1
|
|
Pyridyl inhibitors of hedgehog signalling
|
|
AU2013204025A1
|
|
Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders
|
|
AU2012268819A1
|
|
Raf kinase inhibitors containing a zinc binding moiety
|
|
AU2012261533A1
|
|
Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
|
|
US2013102595A1
|
|
Treatment of cancers having k-ras mutations
|
|
AU2012216752A1
|
|
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
AU2012202431A1
|
|
Tyrosine kinase inhibitors containing a zinc binding moiety
|
